Forum on Neuroscience and Nervous System Disorders
2013 Annual Report
About the Neuroscience Forum
The Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders was established in 2006 to bring together government, industry, academia, patient advocacy organizations, and other interested parties. The Forum meets three times per year and provides its members with a structured, neutral venue for exchanging information, ideas, and differing points of view. At its meetings, the Forum examines significant—and sometimes contentious—issues concerning science, priority setting, and policy related to neuroscience research, nervous system disorders, and the development, regulation, and clinical use of interventions for the nervous system. Based on such discussions, the Forum sponsors workshops (symposia), workshop summaries, and commissioned papers as an additional mechanism for informing its membership, other stakeholders, and the public about emerging issues and matters deserving scrutiny. Information about past and upcoming meetings is available at the Forum’s website, www.iom.edu/neuroforum.
Message from the Chair

The IOM Forum on Neuroscience and Nervous System Disorders brings together the private sector; federal agencies that serve as research sponsors and regulators; the nonprofit sector, including foundations and groups focused on nervous system disease; and the academic community to consider shared approaches to pressing issues.

Through its meetings and public workshops, the Forum provides a venue for its members, other neuroscience leaders, government officials, and members of the public to have rich and candid discussions about issues of mutual interest. In 2013, discussions included diverse topics such as challenges associated with providing evidence-based psychosocial treatments to patients in need; opportunities based on emerging neuroscience technologies to speed potential treatments into first-in-human trials; mechanisms to standardize data analysis in diffusion magnetic resonance imaging (dMRI) to enhance its potential for research and clinical use; and opportunities created by the federal BRAIN Initiative.

Looking ahead to 2014, the Forum plans an array of activities on topics such as

- Strategies for strengthening the connections between basic neuroscientists and translational researchers working on diagnostics and therapeutics;
- Regulatory trends and opportunities to increase private-sector investment in central nervous system (CNS) research and development;
- Improving access to essential medicines for mental, neurological, and substance use disorders in sub-Saharan Africa;
- Examining current practices for training scientists and identifying opportunities for improving training programs in the neurosciences; and
- Opportunities to improve the research community’s access to large basic datasets.

I look forward to another productive year for the Forum.

Steve Hyman
Chair
Reflecting Back
Forum Activities in 2013

Accelerating Therapeutic Development for Nervous System Disorders
Toward First-in-Human Trials
Although there is a high burden associated with nervous system disorders, development of new therapeutics remains stagnant. Current data suggest that a high percentage of drugs intended for nervous system disorders fail in clinical trials. Moreover, for drugs that are eventually marketed, development, from the start of a discovery program to regulatory approval, can take an average of 12 to 15 years. Among the obstacles to successful drug discovery and development are the limitations of current animal models. The Forum hosted a workshop to examine opportunities to accelerate early phases of drug development for nervous system disorders. Participants discussed approaches to using animal models more effectively, emerging uses of in vitro technologies for therapeutics research using human cells reprogrammed into neurons, and how to enable faster entry of potential treatments into first-in-human trials. The workshop explored how new and emerging tools, technologies, and techniques may improve the efficiency of research and considered mechanisms to facilitate a more effective and efficient development pipeline.
Developing Standards for Diffusion Magnetic Resonance Imaging

There is strong interest across many organizations to make faster progress in detecting and monitoring progression of brain injuries, neurodevelopmental disorders, and neurodegenerative diseases. Although the use of diffusion magnetic resonance imaging (dMRI) tools offers great promise, its utility has been held back by a lack of shared standards and clinical validation. Multiple platforms with little, or no, ability to compare results makes it challenging to incorporate dMRI into basic studies of disease and clinical trials. Given the pressing need for better tools, the Forum, together with experts in the field and key stakeholders from both public and private groups, discussed opportunities for developing standards for dMRI that would advance the field without slowing innovation.
Looking Forward
Forum Activities in 2014

Managing and Sharing Large Basic Research Datasets
Neuroscience and allied areas of science are generating ever larger, richer, and more complex datasets. There is tremendous potential for these datasets to improve understanding of the nervous system and the biology of disease and to aid in the development of therapeutics. Data collected from imaging, genomics, and circuitry all highlight the opportunities that might arise from greater understanding and sharing of basic data. However, infrastructure and policies have not been firmly established to ensure successful management, sharing, and sustainability of databases within the global neuroscience community. The Forum will host an activity to address challenges and examine potential opportunities that would facilitate better management and greater sharing of large basic research datasets.

Improving Access to Essential Medicines for Mental, Neurological, and Substance Use Disorders in Sub-Saharan Africa
Sub-Saharan Africa (SSA) has one of the world’s largest treatment gaps for mental, neurological, and substance use (MNS) disorders, causing a substantial burden for the continent’s population. Improving access to essential medicines has been identified as a critical component of reducing the treatment gap for MNS disorders. In an effort to achieve reliable, sustainable access to essential medicines, the Forum will host a meeting that will bring together key stakeholders to discuss opportunities for providing access to essential medicines for MNS disorders. Specifically, participants will examine successful models in a variety of disease areas and in low- and middle-income countries outside SSA. Because of the complex and multifaceted nature of this topic, the meeting will also focus on determining the specific steps and partnerships needed to make drugs accessible.
Non-Invasive Devices for the Treatment of Nervous System Disorders

Based on advances in biotechnology and neuroscience, and given the interest of the federal BRAIN Initiative, non-invasive neuromodulation devices are poised to gain clinical importance in coming years and to be of increasing interest to industry. Emerging evidence suggests that the potential uses of neuromodulation are broad and might expand beyond movement disorders, depression, obsessive-compulsive disorder, epilepsy, and pain to an array of additional conditions, including memory loss, rehabilitation after stroke, addictive disorders, and others. However, along with opportunities, there are challenges, including questions of risk-benefit for invasive devices and ethical questions which extend to the possibility of enhancement (e.g., of mood states or memory) in individuals who are not impaired at baseline. The Forum will host a series of activities to examine opportunities and risks and discuss appropriate regulatory regimes and the concerns of both developers and payers.
Training the Next Generation of Neuroscientists

From its very beginnings, neuroscience has been fundamentally interdisciplinary. As a result of rapid technological advances and the advent of large collaborative projects, however, neuroscience is expanding well beyond its traditional subdisciplines and intellectual boundaries to include more engineering, computer science, and applied mathematics. Revolutionary tools, such as optogenetics and genome engineering tools like CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) are quickly being incorporated into the work of some labs. However, the importance and rapid proliferation of mission-critical technologies raises important questions about how to train the next generation of neuroscientists, not only to use particular tools, but to be prepared for a changing technological landscape. In addition, the advent of new types of data and the growing important of large datasets raise additional questions about how to train the next
generation in approaches to data standardization and sharing and proper analysis. These concerns dovetail with the need to teach improved scientific practices ranging from experimental design (powering of studies, appropriate blinding) to greater sophistication in statistics. Given the changing landscape resulting from technological advance and the growing importance of interdisciplinary and collaborative science, the Forum will host a workshop to explore future workforce needs and consider the needs of training programs. Current and new components of training programs will be discussed in order to identify methods for enhancing data handling and analysis capabilities, increasing scientific rigor, and improving research practices. Finally, the roles of mentors, mentees, training program administrators and funders in the development and execution of revised training programs for new and current researchers will be explored.
Working Groups

The Forum has created a series of working groups to provide an opportunity for subsets of the broader group to work together on selected topics. Workshop topics often result from these groups and are organized by an independently appointed workshop planning committee.

**Mental Health, Neurological, and Substance Use Disorders in Sub-Saharan Africa**

In collaboration with the World Health Organization’s mental health Gap Action Programme, the Forum is continuing to explore additional opportunities to build on its 2009 Mental Health and Neurological Disorders in Sub-Saharan Africa workshop. The working group is focused on identifying innovative solutions to enhance care for MNS disorders in SSA. Special attention is being paid to finding solutions to increase human and financial resources to support current and future efforts.

**Translational Neuroscience**

The translational neuroscience working group was established to identify areas of synergy where public- and private-sector stakeholders can work together to improve the efficiency and effectiveness of drug discovery and development for neurological and mental disorders. The group is currently addressing barriers to repurposing and reusing existing compounds. In addition, the working group is discussing strategies to increase communication and information sharing among pharmaceutical and diagnostic developers and academic researchers. The aim of such communication is to inform researchers about how they can contribute to partnerships in a meaningful way, with the goal of improving the neuroscience translational therapeutic development pipeline.
Enabling Neuroscience Research and Development

The Forum is establishing a working group that will explore potential financial incentives that could spur additional investment from the private sector in translational neuroscience research and development. To begin this effort, the Forum expects to commission a paper that will perform a financial analysis of two or three incentives that could lead to significant reinvestment by large pharmaceutical companies in CNS disorders. This analysis would include the cost to society and how much it would cost payers if a therapeutic drug were delayed from transitioning to a generic.
2013 Publications

Improving the Utility and Translation of Animal Models for Nervous System Disorders – Workshop Summary

Neurodegeneration: Exploring Commonalities Across Diseases – Workshop Summary

- June 17: 22nd meeting
- Oct 28: 23rd meeting
- Nov 15: Meeting on Dry AMD
Sharing Clinical Research Data - Workshop Summary

Strengthening Human Resources Through Development of Candidate Core Competencies for Mental, Neurological, and Substance Use Disorders in Sub-Saharan Africa - Workshop Summary
Forum Members
(as of December 2013)

Steven Hyman (Chair)
Broad Institute of the Massachusetts Institute of Technology and Harvard

Susan Amara
Society for Neuroscience

Mark Bear
Massachusetts Institute of Technology

Katja Brose
Cell Press

Daniel Burch
Pharmaceutical Product Development, Inc.

Maria Carrillo
Alzheimer’s Association

C. Thomas Caskey
Baylor College of Medicine

Timothy Coetzee
FastForward of the National Multiple Sclerosis Society

Emmeline Edwards
National Center for Complementary and Alternative Medicine

Martha Farah
University of Pennsylvania

Daniel Geschwind
University of California, Los Angeles

Hank Greely
Stanford University

Magali Haas
One Mind for Research

Richard Hodes
National Institute on Aging

Stuart Hoffman
Department of Veteran Affairs

Thomas Insel
National Institute of Mental Health

Phillip Iredale
Pfizer, Global Research and Development

Daniel Javitt
Columbia University

Frances Jensen
University of Pennsylvania Health System

Story Landis
National Institute of Neurological Disorders and Stroke

Alan Leshner
American Association for the Advancement of Science

Husseini Manji
Johnson & Johnson Pharmaceuticals

David Michelson
Merck Research Laboratories

Richard Mohs
Eli Lilly and Company

Jonathan Moreno
University of Pennsylvania School of Medicine

Atul Pande
GlaxoSmithKline

Steven Paul
Weill Cornell Medical College

Todd Sherer
The Michael J. Fox Foundation for Parkinson’s Research

Paul Sieving
National Eye Institute

Joanne Tornow
National Science Foundation

Nora Volkow
National Institute on Drug Abuse

Kenneth Warren
National Institute on Alcohol Abuse and Alcoholism

David Wholley
Foundation for the National Institutes of Health

John Williams
Wellcome Trust

Stevin Zorn
Lundbeck USA

Charles Zorumski
Washington University School of Medicine

IOM Staff
Bruce Altevogt, Ph.D.
Project Director

Diana Pankevich, Ph.D.
Program Officer

Sheena Posey Norris, M.S.
Research Associate

Rachel Kirkland, M.A.
Senior Program Assistant

Andrew M. Pope, Ph.D.
Director, IOM Board on Health Sciences Policy
Sponsors
(as of December 2013)

Financial support for the Forum is derived from federal agencies, patient advocacy organizations, industry, and a nonprofit membership society.

Alzheimer’s Association
Department of Veterans Affairs
Foundation for the National Institutes of Health
GlaxoSmithKline
Johnson & Johnson Pharmaceuticals
Lilly Research Laboratories
Lundbeck USA
Merck Research Laboratories
The Michael J. Fox Foundation for Parkinson’s Research
National Eye Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute on Drug Abuse
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
National Institutes of Health Blueprint for Neuroscience Research
National Multiple Sclerosis Society
National Science Foundation
One Mind for Research
Pharmaceutical Product Development, Inc.
Pfizer, Global Research and Development
Society for Neuroscience
Wellcome Trust
The Institute of Medicine serves as adviser to the nation to improve health. Established in 1970 under the charter of the National Academy of Sciences, the Institute of Medicine provides independent, objective, evidence-based advice to policymakers, health professionals, the private sector, and the public. The mission of the Institute of Medicine embraces the health of people everywhere.